SG11201606684YA - Anti-pcsk9~glp-1 fusions and methods for use - Google Patents

Anti-pcsk9~glp-1 fusions and methods for use

Info

Publication number
SG11201606684YA
SG11201606684YA SG11201606684YA SG11201606684YA SG11201606684YA SG 11201606684Y A SG11201606684Y A SG 11201606684YA SG 11201606684Y A SG11201606684Y A SG 11201606684YA SG 11201606684Y A SG11201606684Y A SG 11201606684YA SG 11201606684Y A SG11201606684Y A SG 11201606684YA
Authority
SG
Singapore
Prior art keywords
pcsk9
glp
fusions
methods
Prior art date
Application number
SG11201606684YA
Inventor
Anthony Celeste
Matthieu Chodorge
Andrew Buchanan
Cristina Rondinone
Joseph Grimsby
Peter Ravn
Jonathan Seaman
David Fairman
Original Assignee
Medimmune Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Medimmune Ltd filed Critical Medimmune Llc
Publication of SG11201606684YA publication Critical patent/SG11201606684YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
SG11201606684YA 2014-02-21 2015-02-20 Anti-pcsk9~glp-1 fusions and methods for use SG11201606684YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943300P 2014-02-21 2014-02-21
US201461944550P 2014-02-25 2014-02-25
PCT/US2015/016911 WO2015127273A1 (en) 2014-02-21 2015-02-20 Anti-pcsk9~glp-1 fusions and methods for use

Publications (1)

Publication Number Publication Date
SG11201606684YA true SG11201606684YA (en) 2016-09-29

Family

ID=53879052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606684YA SG11201606684YA (en) 2014-02-21 2015-02-20 Anti-pcsk9~glp-1 fusions and methods for use

Country Status (12)

Country Link
US (1) US10077319B2 (en)
EP (1) EP3107937A4 (en)
JP (1) JP2017512457A (en)
KR (1) KR20160124787A (en)
CN (1) CN106232627A (en)
BR (1) BR112016017402A2 (en)
CA (1) CA2935285A1 (en)
MX (1) MX2016009858A (en)
RU (1) RU2016137264A (en)
SG (1) SG11201606684YA (en)
TW (1) TW201538523A (en)
WO (1) WO2015127273A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
CN107148430B (en) 2014-08-19 2021-08-27 默沙东公司 anti-TIGIT antibody
JP6976241B2 (en) 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Anti-TIGIT antibody
JP6797926B2 (en) 2016-01-13 2020-12-09 ノヴォ ノルディスク アー／エス EGF (A) analog with fatty acid substituent
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US10633434B2 (en) 2016-06-14 2020-04-28 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
WO2019016306A1 (en) * 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
JP2021506241A (en) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Anti-C5 antibody combination and its use
TW202028229A (en) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 Bifunctional compounds comprising insulin peptides and egf(a) peptides
CN115380043A (en) * 2019-08-13 2022-11-22 安医健有限公司 Exenatide analogue and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074600A1 (en) 2005-01-14 2006-07-20 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
EP2818181B1 (en) * 2007-01-08 2018-10-24 The Trustees Of The University Of Pennsylvania Compositions and medical uses thereof
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
CN102481373A (en) * 2009-03-27 2012-05-30 葛兰素集团有限公司 Drug fusions and conjugates
CN101665799A (en) 2009-06-29 2010-03-10 华东师范大学 Recombination preparation method and application of Exendin-4 derivative
CN101993485B (en) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
MX2012010481A (en) * 2010-03-11 2012-10-09 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING.
US9187552B2 (en) * 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI513705B (en) 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4

Also Published As

Publication number Publication date
US10077319B2 (en) 2018-09-18
BR112016017402A2 (en) 2017-10-17
RU2016137264A (en) 2018-03-26
EP3107937A4 (en) 2017-11-15
US20160369010A1 (en) 2016-12-22
RU2016137264A3 (en) 2018-11-30
CA2935285A1 (en) 2015-08-27
EP3107937A1 (en) 2016-12-28
KR20160124787A (en) 2016-10-28
JP2017512457A (en) 2017-05-25
WO2015127273A1 (en) 2015-08-27
TW201538523A (en) 2015-10-16
CN106232627A (en) 2016-12-14
MX2016009858A (en) 2017-01-26

Similar Documents

Publication Publication Date Title
IL250415B (en) Anti-pdl- antibodies and methods of use thereof
SG11201606684YA (en) Anti-pcsk9~glp-1 fusions and methods for use
ZA201605626B (en) Long-acting insulin and use thereof
PL3063275T3 (en) Therapeutic nuclease-albumin fusions and methods
IL251988A0 (en) Glycan-interacting compounds and methods of use
HRP20190432T1 (en) Pladienolide pyridine compounds and methods of use
LT3089971T (en) Compounds and methods of use
SG11201704473WA (en) New methods and uses
IL247159B (en) Pcsk9 vaccines
GB201416293D0 (en) Methods and preparations
HK1243342A1 (en) Compounds and methods
GB201403944D0 (en) New use
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
HK1243105A1 (en) High activity tumour inhibitor and preparation method and use thereof
IL247797A0 (en) Glucometer and method for use
GB201420095D0 (en) New use
GB201403697D0 (en) Compounds and methods of use
GB201418727D0 (en) Forehearths and burner blocks for use therein
GB201415302D0 (en) New therapeutic use